Denali Therapeutics Inc. Interest Receivable, Current
Denali Therapeutics Inc. (DNLI) had Interest Receivable, Current of $1.18 million as of 2018-12-31, per its 10-K filed 2019-03-12.
Discontinued › Notes
us-gaap:InterestReceivableCurrent · last filed 2019-03-12
- 2018-12-31: Interest Receivable, Current $1.18M.
- 2017-12-31: Interest Receivable, Current $464.00K.
| Period end | Interest Receivable, Current |
|---|---|
| 2018-12-31 | $1.18M 10-K · filed 2019-03-12 |
| 2017-12-31 | $464.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |